TL;DR
This study reveals that Sphingosine Kinase 1 (SPHK1) in smooth muscle cells is a key driver of hypoxia-induced pulmonary hypertension (PH). By specifically knocking out SPHK1 in these cells, researchers found protection against PH development. This protective effect is mediated through the YAP1 signaling pathway, suggesting that targeting YAP1 could be a promising therapeutic strategy for PH.
What Problem Does This Paper Address?
Pulmonary arterial hypertension (PAH) is a severe and progressive disease characterized by increased pulmonary vascular resistance, leading to right heart failure and death. A major contributor to this resistance is pulmonary vascular remodeling, driven by the excessive proliferation and resistance to apoptosis of pulmonary artery smooth muscle cells (PASMCs). While current PAH therapies primarily target vasoconstriction, there's a critical need for new strategies to combat vascular remodeling. Previous work hinted at the involvement of the sphingosine kinase 1 (SPHK1)/sphingosine-1-phosphate (S1P) pathway in PAH, but its specific role in PASMCs and its connection to remodeling remained unclear. This paper aims to elucidate the precise role of SPHK1 in PASMCs during PH progression and to identify the downstream signaling mechanisms involved.
Methods
The researchers employed a multi-pronged approach combining in vivo and in vitro studies:
- Genetic Manipulation: They generated smooth muscle cell-specific SPHK1 knockout mice (Sphk1<sup>f/f</sup> TaglnCre<sup>+</sup>) by breeding Sphk1<sup>f/f</sup> mice with TaglnCre<sup>+</sup> mice. This allowed them to specifically delete SPHK1 in PASMCs. They also used global SPHK1 knockout mice (Sphk1<sup>-/-</sup>) for in vitro studies.
- PH Models: They utilized established rodent models of PH, including chronic hypoxia-induced PH in mice and hypoxia/Sugen-induced PH in both mice and rats. Monocrotaline (MCT)-induced PH in rats was also used.
- Immunofluorescence Staining: This technique was used to visualize and quantify SPHK1 protein expression in lung tissues and to assess YAP1 nuclear translocation in PASMCs.
- Western Blotting: Used to measure protein levels of YAP1, TAZ, SPHK1, and S1PR2 in lung tissues and cell lysates.
- Cell-Based Assays:
- Proliferation Assays: BrdU incorporation assays and cell counting were used to assess PASMC proliferation.
- Viability and Apoptosis Assays: Cell Titer 96 AQueous One Solution Cell Proliferation Assay and TUNEL assays were employed to measure cell viability and apoptosis, respectively. Lactate dehydrogenase (LDH) assay was used as a measure of cell death.
- Pharmacological Inhibition: Verteporfin, a known YAP1 inhibitor, was used to assess the role of YAP1 in PH and S1P-mediated effects. JTE-013, an S1PR2 antagonist, was used to investigate the role of S1PR2.
- RNA Interference (siRNA): siRNA was used to silence SPHK1 and S1PR2 expression in hPASMCs to study their specific roles.
- Hemodynamic Measurements: Right ventricular systolic pressure (RVSP) was measured using right heart catheterization to assess PH severity. Right ventricular hypertrophy (RVH) was assessed by the RV/(LV+S) ratio.
- Histological Analysis: Pulmonary artery remodeling was evaluated by measuring the wall area to total vessel area ratio in pulmonary arteries of different sizes.
Datasets
Not discussed in the paper.
Key Insights and Ideas
- SPHK1 is a key player in PASMC proliferation and PH: The study firmly establishes that SPHK1 is upregulated in PASMCs during PH and that its absence in these cells confers significant protection against PH development. This highlights SPHK1 as a critical mediator of vascular remodeling.
- SPHK1 deficiency protects against multiple PH models: The protective effect of smooth muscle cell-specific SPHK1 knockout was observed in both hypoxia-induced and hypoxia/Sugen-induced PH models, underscoring its broad relevance.
- YAP1 is the downstream effector: The research demonstrates that S1P and hypoxia activate YAP1 signaling by promoting its nuclear translocation. This YAP1 activation is dependent on SPHK1's enzymatic activity.
- YAP1 inhibition mimics SPHK1 deficiency: Pharmacological inhibition of YAP1 with verteporfin effectively attenuated hypoxia-induced PH and vascular remodeling, mirroring the effects seen in SPHK1 knockout mice. This strongly links SPHK1 to YAP1 in the pathogenesis of PH.
- SPHK1/S1P/S1PR2 axis is crucial for YAP1 activation: The study shows that S1P promotes YAP1 nuclear translocation via S1PR2 ligation, and SPHK1 is essential for this process.
- YAP1's role in PASMC survival: YAP1 appears to repress apoptosis and promote pro-survival phenotypes in PASMCs, suggesting that its dysregulation contributes to the disease.
Key Results
- SPHK1 upregulation: SPHK1 protein levels were significantly increased in PASMCs from rodent models of PH.
- Protection from PH: Sphk1<sup>f/f</sup> TaglnCre<sup>+</sup> mice (smooth muscle cell-specific SPHK1 knockout) showed significantly lower RVSP, reduced RVH, and less pulmonary vascular remodeling compared to wild-type littermates when exposed to hypoxia or hypoxia/Sugen.
- Reduced PASMC proliferation: PASMCs isolated from Sphk1<sup>-/-</sup> mice were less proliferative and less viable than those from wild-type mice.
- YAP1 activation: Hypoxia and S1P treatment significantly increased YAP1 nuclear translocation in hPASMCs. This effect was dependent on SPHK1 activity.
- Verteporfin efficacy: Treatment with verteporfin attenuated hypoxia-mediated PH in mice and hypoxia/Sugen-mediated PH in rats, reducing RVSP, RVH, and vascular remodeling.
- S1P signaling via S1PR2: S1P-induced YAP1 nuclear translocation was mediated through S1PR2.
Limitations and Future Work
- Role of Sugen: The paper notes that the specific role of Sugen in enhancing hypoxia-induced YAP1 is unclear, and it would be interesting to determine if Sugen alone affects SPHK1 expression in mouse PASMCs.
- TAZ expression: While hypoxia increased both YAP1 and TAZ expression, S1P's effect on TAZ was marginal. The authors suggest that S1P might alter YAP1/TAZ interactions without changing TAZ expression, or that hypoxia-mediated TAZ upregulation is independent of the S1P signaling axis. Future studies using SPHK1 conditional knockout mice are needed to investigate these differences.
- Sugen's effect on S1PR2: It remains to be determined if Sugen alone or hypoxia + Sugen affects the expression of S1PR2 and other S1PRs in PASMCs in the context of PAH development.
- Therapeutic potential: The study strongly suggests YAP1 inhibition as a therapeutic target. Future work could focus on developing more specific and effective YAP1 inhibitors for PAH treatment.
- Mechanistic details: Further investigation into the precise mechanisms by which SPHK1/S1P signaling influences YAP1 activation and its downstream effects on PASMC behavior is warranted.
Summary updated